Transcription of Reference ID: 4110010 - VELCADE
{{id}} {{{paragraph}}}
Example: bankruptcy
Reference ID: 4110010 - VELCADE
1/38 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VELCADE safely and effectively. See full prescribing information for VELCADE . VELCADE (bortezomib) for injection, for subcutaneous or intravenous use Initial Approval: 2003 ------------------------RECENT MAJOR CHANGES------------------------- Warnings and Precautions ( ) 6/2017 ------------------------INDICATIONS AND USAGE-------------------------- VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma ( ) treatment of patients with mantle cell lymphoma ( ) ----------------------DOSAGE AND ADMINISTRATION--------------------- For subcutaneous or intravenous use only. Each route of administration has a different reconstituted concentration; Exercise caution when calculating the volume to be administered.
4/38 2.3 Dose Modification Guidelines for VELCADE When Given in Combination with Melphalan and Prednisone . Prior to initiating any cycle of therapy with VELCADE in combination with melphalan and prednisone:
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: